End-of-day quote
Taipei Exchange
06:00:00 2024-04-25 pm EDT
|
5-day change
|
1st Jan Change
|
35.4
TWD
|
+0.28%
|
|
-0.56%
|
-3.67%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
1,248
|
1,463
|
3,717
|
2,147
|
1,445
|
1,345
|
Enterprise Value (EV)
1 |
1,276
|
1,368
|
3,561
|
2,077
|
1,066
|
847.9
|
P/E ratio
|
13.5
x
|
12.4
x
|
6.96
x
|
6.81
x
|
14.3
x
|
31.5
x
|
Yield
|
-
|
-
|
-
|
10.5%
|
5.09%
|
2.72%
|
Capitalization / Revenue
|
0.94
x
|
1.17
x
|
1.43
x
|
0.92
x
|
1.2
x
|
1.53
x
|
EV / Revenue
|
0.96
x
|
1.1
x
|
1.37
x
|
0.89
x
|
0.89
x
|
0.96
x
|
EV / EBITDA
|
8.14
x
|
6.64
x
|
5.09
x
|
4.6
x
|
6.12
x
|
11.7
x
|
EV / FCF
|
10.3
x
|
8.65
x
|
31.9
x
|
22.7
x
|
2.86
x
|
5.53
x
|
FCF Yield
|
9.7%
|
11.6%
|
3.13%
|
4.4%
|
35%
|
18.1%
|
Price to Book
|
2.87
x
|
2.83
x
|
4.09
x
|
2.27
x
|
1.59
x
|
1.51
x
|
Nbr of stocks (in thousands)
|
32,088
|
31,117
|
36,444
|
36,444
|
36,769
|
36,603
|
Reference price
2 |
38.90
|
47.00
|
102.0
|
58.90
|
39.30
|
36.75
|
Announcement Date
|
3/26/19
|
3/30/20
|
3/26/21
|
5/31/22
|
3/25/23
|
3/20/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
1,327
|
1,248
|
2,600
|
2,325
|
1,201
|
879.1
|
EBITDA
1 |
156.8
|
205.9
|
699.1
|
451.4
|
174.1
|
72.64
|
EBIT
1 |
130.2
|
176.8
|
664.4
|
390.5
|
116.5
|
14.9
|
Operating Margin
|
9.81%
|
14.17%
|
25.55%
|
16.8%
|
9.7%
|
1.69%
|
Earnings before Tax (EBT)
1 |
123.9
|
168.4
|
648.9
|
391.4
|
136.5
|
41.61
|
Net income
1 |
98.82
|
130.9
|
520.1
|
315.5
|
101.1
|
42.72
|
Net margin
|
7.45%
|
10.5%
|
20%
|
13.57%
|
8.42%
|
4.86%
|
EPS
2 |
2.873
|
3.776
|
14.66
|
8.647
|
2.750
|
1.167
|
Free Cash Flow
1 |
123.8
|
158.2
|
111.6
|
91.46
|
372.9
|
153.3
|
FCF margin
|
9.33%
|
12.68%
|
4.29%
|
3.93%
|
31.05%
|
17.44%
|
FCF Conversion (EBITDA)
|
78.92%
|
76.85%
|
15.96%
|
20.26%
|
214.16%
|
211.11%
|
FCF Conversion (Net income)
|
125.25%
|
120.83%
|
21.45%
|
28.99%
|
368.75%
|
358.98%
|
Dividend per Share
|
-
|
-
|
-
|
6.200
|
2.000
|
1.000
|
Announcement Date
|
3/26/19
|
3/30/20
|
3/26/21
|
5/31/22
|
3/25/23
|
3/20/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
27.8
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
94.6
|
156
|
69.7
|
379
|
497
|
Leverage (Debt/EBITDA)
|
0.1773
x
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
124
|
158
|
112
|
91.5
|
373
|
153
|
ROE (net income / shareholders' equity)
|
22.8%
|
27.6%
|
72.5%
|
33.9%
|
10.9%
|
4.75%
|
ROA (Net income/ Total Assets)
|
7.9%
|
10.4%
|
23.2%
|
11.5%
|
4.8%
|
0.72%
|
Assets
1 |
1,252
|
1,257
|
2,238
|
2,732
|
2,106
|
5,912
|
Book Value Per Share
2 |
13.50
|
16.60
|
25.00
|
25.90
|
24.80
|
24.30
|
Cash Flow per Share
2 |
8.430
|
8.810
|
14.50
|
7.970
|
10.70
|
11.60
|
Capex
1 |
31.9
|
44.4
|
197
|
71.4
|
63.6
|
29.9
|
Capex / Sales
|
2.4%
|
3.55%
|
7.56%
|
3.07%
|
5.3%
|
3.4%
|
Announcement Date
|
3/26/19
|
3/30/20
|
3/26/21
|
5/31/22
|
3/25/23
|
3/20/24
|
|
1st Jan change
|
Capi.
|
---|
| -3.67% | 39.72M | | +73.17% | 12.38B | | -18.74% | 7.92B | | +16.15% | 7.2B | | +5.26% | 5.84B | | +5.99% | 5.07B | | +27.07% | 4.53B | | -21.67% | 3.88B | | -40.82% | 2.23B | | +1.36% | 2.02B |
Medical Equipment
|